Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
ID: 343054Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/343054

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-215.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This initiative encourages applicants to utilize animal models alongside human translational and clinical approaches, leveraging advancements in genetics and other interdisciplinary methods to explore genetic, epigenetic, and environmental interactions related to birth defects. Given that nearly three percent of live births in the U.S. are affected by such defects, this research is crucial for public health and economic considerations. The maximum funding amount per application is $499,999 annually, with project periods lasting up to five years, and the application deadline is September 7, 2025. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-22-215-Full-Announcement.html
    PAR-22-215.html
    The Department of Health and Human Services' funding opportunity, led by the National Institutes of Health (NIH), focuses on "Advancing Research to Understand Congenital Malformations" through R01 Research Project Grants. This initiative aims to enhance the understanding of the mechanisms behind structural birth defects using animal models alongside human clinical approaches, leveraging advancements in genetics and other interdisciplinary methods. Applicants are encouraged to explore genetic, epigenetic, environmental interactions linked to structural birth defects and to form collaborative teams involving both basic and clinical scientists. With nearly three percent of live births in the U.S. involving birth defects, this research is vital due to its implications for public health and economic costs. The maximum budget allowed per application is $499,999 annually, with project periods lasting up to five years. The grant does not permit clinical trials and emphasizes a robust methodology in applications. It outlines clear eligibility criteria for applicant organizations and individuals, including educational institutions and nonprofit organizations. Lastly, the submission process requires adherence to specific guidelines to ensure compliance and successful evaluation by NIH, reinforcing the initiative's goal of fostering innovative, impactful research in understanding and preventing birth defects.
    Similar Opportunities
    Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)" aimed at advancing research on congenital defects linked to genetic variants. This initiative encourages the use of cutting-edge genotyping and sequencing technologies to validate genetic variants identified through public databases, bridging the gap between variant identification and understanding their functional impacts on developmental outcomes. The funding is available to a diverse range of eligible organizations, including higher education institutions and nonprofits, with an annual budget cap of $499,999 and a project period of up to five years. Interested applicants should contact the NIH OER Webmaster at grantsinfo@nih.gov for assistance and must submit their proposals by May 7, 2025, to be considered for this significant funding opportunity.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)." This initiative invites applications aimed at improving the utility of mammalian cancer models, including organoids and tumoroids, to better represent human biology and address translational deficiencies in existing models. The funding seeks to advance cancer research by fostering innovative approaches to validate these models and enhance their clinical relevance, ultimately aiming to improve patient outcomes. Eligible applicants can receive up to $499,000 per year for a maximum of five years, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html.
    Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research into the natural history of disorders detectable through newborn screening, under the grant title "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)." This initiative aims to enhance understanding of these disorders to support early identification and intervention, focusing on improving diagnostic accuracy, elucidating genetic and clinical heterogeneity, and exploring underlying mechanisms to inform treatment options. The funding is available for new, renewal, resubmission, or revision applications, with a maximum support period of five years and no cost-sharing requirement. Interested applicants, including various educational and community organizations, must submit proposals by January 7, 2025, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance or further information.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at encouraging research into novel screening methods and therapeutic interventions for serious genetic and congenital conditions identified through newborn screening. This initiative, under the R03 Small Grant Program, supports small-scale projects lasting up to two years with a budget of up to $50,000 per year, focusing on developing robust screening technologies to enhance early detection and treatment of disorders, thereby minimizing long-term health consequences. The program is particularly important for addressing high-priority conditions where screening is not currently recommended, and it emphasizes inclusivity in research by inviting applications from a diverse range of organizations, including higher education institutions and community-based organizations. Interested applicants should note that the application deadline is November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for in-depth phenotyping and research using knockout (KO) mouse strains that exhibit embryonic or perinatal lethality or subviability, under the R01 Research Project Grant mechanism (Funding Opportunity Announcement PAR-23-074). This initiative encourages applications to perform detailed phenotyping on specific KO mouse cohorts or to utilize these strains in hypothesis-driven research related to congenital diseases and fertility issues, contributing to the mission of the International Mouse Phenotyping Consortium (IMPC) to catalog mammalian gene functions. The funding amount can reach up to $499,999 per year for a duration of five years, with applications due by January 7, 2026. Interested applicants can find more information and guidance on the submission process at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Resource-Related Research Projects for Development of Animal Models and Related Materials (R24 Clinical Trials Not-Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Resource-Related Research Projects for Development of Animal Models and Related Materials," aimed at advancing research that develops and enhances animal models relevant to human diseases. The initiative seeks applications that demonstrate the need for and potential impact of broadly applicable resources across multiple NIH Institutes and Centers, emphasizing projects that address diseases affecting multiple body systems rather than those focused on specific diseases or singular NIH interests. Eligible applicants include higher education institutions, nonprofit organizations, and government agencies, with funding available up to $5 million per year. The application deadline is set for January 25, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    The Road to Prevention of Stillbirth Clinical Research Centers (UG1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Road to Prevention of Stillbirth – Clinical Research Centers" funding opportunity, aimed at establishing Research Centers within the Stillbirth Research Consortium. This initiative focuses on reducing the incidence of stillbirth in vulnerable populations through interdisciplinary research, with key objectives including the development of clinical tools, understanding mechanisms contributing to stillbirth, and enhancing maternal-fetal communication. The program emphasizes collaboration among diverse research teams and requires a Plan for Enhancing Diverse Perspectives and a Plan for Inclusion of People with Lived Experience. An estimated $4.3 million in direct costs is available, with awards expected to support 3-5 projects, each with a maximum budget of $860,000 annually for up to 5 years. Interested applicants must submit preliminary letters of intent and adhere to comprehensive submission guidelines by the closing date of November 1, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at developing novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening. This initiative encourages diverse scientific research focused on improving screening technologies, therapeutic interventions, and preclinical testing, particularly for "high priority" genetic conditions that are not currently recommended for screening but could benefit from early identification and treatment. Eligible applicants include a wide range of organizations, such as educational institutions, community-based organizations, and tribal governments, with applications due by November 5, 2024. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-21-353.html.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing research in drug safety and effectiveness for pregnant individuals, lactating persons, and children. This initiative seeks to support innovative projects that develop novel methodologies, enhance understanding of drug mechanisms, and promote precision medicine to address significant unmet medical needs in maternal and pediatric health. Eligible applicants include a wide range of institutions, such as historically black colleges and universities, tribal colleges, and various nonprofit organizations, with funding available up to $275,000 over a two-year period. Interested parties should note that applications are accepted until December 16, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for innovative research aimed at developing screening approaches and therapies for screenable disorders in newborns, designated as R21 - Clinical Trial Optional. This initiative encourages projects that focus on creating novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening, particularly emphasizing early diagnosis and treatment to improve health outcomes. The program is part of NIH's commitment to advancing public health and reducing health disparities, with a funding ceiling of $275,000 available over a two-year period. Interested applicants, including a diverse range of institutions and organizations, must submit their proposals by November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.